CUE Cue Biopharma, Inc. Stock Quote

CUE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	3.20%	Shs Outstand	32.64M	Perf Week	-18.33%
Market Cap	88.10M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	-	Shs Float	29.35M	Perf Month	-33.78%
Income	-45.90M	PEG	-	EPS next Q	-0.44	Inst Own	51.00%	Short Float	12.21%	Perf Quarter	-49.80%
Sales	14.40M	P/S	6.12	EPS this Y	9.60%	Inst Trans	8.11%	Short Ratio	6.83	Perf Half Y	-78.51%
Book/sh	1.98	P/B	1.24	EPS next Y	-8.70%	ROA	-53.60%	Target Price	24.17	Perf Year	-80.02%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-68.90%	52W Range	2.45 - 18.42	Perf YTD	-78.34%
Dividend	-	P/FCF	-	EPS past 5Y	-25.10%	ROI	-67.50%	52W High	-86.70%	Beta	1.74
Dividend %	-	Quick Ratio	6.70	Sales past 5Y	-	Gross Margin	-	52W Low	-0.20%	ATR	0.33
Employees	57	Current Ratio	6.70	Sales Q/Q	-37.50%	Oper. Margin	-	RSI (14)	32.46	Volatility	12.20% 9.85%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	-6.30%	Profit Margin	-	Rel Volume	0.62	Prev Close	2.49
Shortable	Yes	LT Debt/Eq	0.15	Earnings	-	Payout	-	Avg Volume	524.87K	Price	2.45
Recom	1.50	SMA20	-24.13%	SMA50	-32.21%	SMA200	-70.70%	Volume	323,715	Change	-1.61%

Jan-13-22

Initiated

H.C. Wainwright

Buy

$20

Jan-03-22

Initiated

Craig Hallum

Buy

$28

Nov-24-20

Initiated

Berenberg

Buy

$30

Apr-09-20

Initiated

Stifel

Buy

$21

Jan-28-20

Initiated

BTIG Research

Buy

$26

Jan-22-20

Initiated

JMP Securities

Mkt Outperform

$22

Jun-27-22 10:49AM	Shareholders in Cue Biopharma (NASDAQ:CUE) are in the red if they invested a year ago Simply Wall St. -5.00%
Jun-13-22 08:00AM	Cue Biopharma to Present at the JMP Securities Life Sciences Conference GlobeNewswire -6.25%
Jun-02-22 06:56AM	Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money Simply Wall St.
Jun-01-22 08:00AM	Cue Biopharma to Present at the Jefferies Healthcare Conference GlobeNewswire
May-26-22 05:00PM	Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-11-22 08:00AM	Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms Tumor 1 (WT1) - expressing cancers GlobeNewswire -15.00%
May-10-22 04:30PM	Cue Biopharma Reports First Quarter 2022 Financial Results GlobeNewswire
11:23AM	A Cue Biopharma, Inc. (NASDAQ:CUE) insider increased their holdings by 6.5% last year Simply Wall St.
May-06-22 08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates Zacks
May-05-22 09:45AM	Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates Zacks -7.19%
May-04-22 06:25PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates Zacks
Apr-05-22 09:09PM	2 Stocks Under $10 That This Insider Is Aggressively Buying TipRanks
Apr-04-22 09:06AM	Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength? Zacks +5.78%
Mar-23-22 09:25AM	Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates Zacks
Mar-19-22 08:19AM	Analysts Are Upgrading Cue Biopharma, Inc. (NASDAQ:CUE) After Its Latest Results Simply Wall St.
Mar-10-22 08:00AM	Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference GlobeNewswire
Mar-09-22 05:15PM	ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates Zacks
Mar-02-22 08:00AM	Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress GlobeNewswire
Feb-24-22 05:40PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates Zacks +5.71%
Feb-23-22 09:00PM	Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates Zacks
Feb-15-22 08:22AM	Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar? Zacks +5.97%
08:00AM	Cue Biopharmas Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting GlobeNewswire
Feb-13-22 06:28PM	3 Strong Buy Stocks Trading at Rock-Bottom Prices TipRanks
08:46AM	What Percentage Of Cue Biopharma, Inc. (NASDAQ:CUE) Shares Do Insiders Own? Simply Wall St.
Jan-27-22 05:24AM	Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock? Zacks -24.62%
Jan-26-22 04:01PM	Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer GlobeNewswire +8.27%
Jan-20-22 08:00AM	Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials GlobeNewswire
Jan-05-22 08:00AM	Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102 GlobeNewswire -8.47%
Dec-30-21 05:49AM	Investors in Cue Biopharma (NASDAQ:CUE) have made a solid return of 122% over the past three years Simply Wall St.
Dec-15-21 08:00AM	Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer GlobeNewswire
Dec-06-21 08:00AM	Cue Biopharma to Present at JMP Securities Hematology and Oncology Summit GlobeNewswire
Nov-22-21 08:00AM	Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference GlobeNewswire
Nov-15-21 05:42AM	We're Hopeful That Cue Biopharma (NASDAQ:CUE) Will Use Its Cash Wisely Simply Wall St. +7.79%
Nov-12-21 08:00AM	Cue Biopharma Presents Updated Data from Lead Program CUE-101 for the Treatment of Recurrent/Metastatic HPV+ Head and Neck Cancer and Additional Pipeline Progress at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting GlobeNewswire +9.81%
Nov-10-21 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November GlobeNewswire +5.71%
Nov-09-21 03:00PM	Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-21-21 12:00PM	Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases GlobeNewswire
Oct-04-21 08:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting GlobeNewswire -11.02%
Oct-01-21 06:22AM	The CEO & Director of Cue Biopharma, Inc. (NASDAQ:CUE), Daniel Passeri, Just Bought 6.5% More Shares Simply Wall St.
Sep-28-21 08:00AM	Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT and Neo-STAT GlobeNewswire
Sep-21-21 08:00AM	Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101 GlobeNewswire +5.74%
Sep-09-21 08:00AM	Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences GlobeNewswire
Aug-23-21 07:04AM	Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders? Simply Wall St.
Aug-17-21 04:01PM	Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights GlobeNewswire
Aug-10-21 08:00AM	Cue Biopharma to Host Business Update Call and Webcast GlobeNewswire
Aug-03-21 08:00AM	Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference GlobeNewswire
Jul-30-21 03:00PM	Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline Zacks
Jun-14-21 08:00AM	Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference GlobeNewswire
Jun-10-21 08:00AM	Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC GlobeNewswire
Jun-03-21 08:30AM	Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting GlobeNewswire
May-26-21 08:00AM	Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference GlobeNewswire +9.00%
May-24-21 02:18AM	Cue Biopharma's (NASDAQ:CUE) Stock Price Has Reduced 53% In The Past Year Simply Wall St.
May-17-21 04:01PM	Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights GlobeNewswire
May-11-21 08:42AM	Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength? Zacks
May-10-21 01:14PM	Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study Benzinga +27.71%
10:00AM	Cue Biopharma to Host Business Update Call and Webcast GlobeNewswire
08:00AM	Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer GlobeNewswire
May-06-21 08:00AM	Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference GlobeNewswire
Apr-09-21 02:14AM	We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate Simply Wall St.
Mar-16-21 04:01PM	Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights GlobeNewswire
Mar-15-21 08:00AM	Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference GlobeNewswire
Mar-09-21 08:00AM	Cue Biopharma to Host Business Update Call and Webcast GlobeNewswire +7.08%
Mar-01-21 08:00AM	Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference GlobeNewswire
Feb-25-21 08:00AM	Cue Biopharma Enhances Scientific Advisory Board with Appointments of Immunology and Immunotherapy Experts Dr. Abul K. Abbas and Dr. Michael Kalos GlobeNewswire
Feb-23-21 12:17AM	What Is The Ownership Structure Like For Cue Biopharma, Inc. (NASDAQ:CUE)? Simply Wall St.
Feb-22-21 08:00AM	Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference GlobeNewswire -5.87%
Feb-17-21 08:00AM	Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development GlobeNewswire
Feb-08-21 08:00AM	Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer GlobeNewswire +8.50%
Jan-29-21 03:34PM	7 Stocks With Insider Buying This Week Worth A Look InvestorPlace
Jan-09-21 02:27AM	How Much Are Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Spending On Buying Shares? Simply Wall St.
Dec-15-20 10:30PM	Is CUE A Good Stock To Buy Now? Insider Monkey
Dec-07-20 08:53AM	Do Options Traders Know Something About Cue Biopharma (CUE) Stock We Don't? Zacks
Nov-25-20 12:02AM	News Flash: Analysts Just Made A Substantial Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Forecasts Simply Wall St.
Nov-24-20 09:51AM	Benzinga's Top Upgrades, Downgrades For November 24, 2020 Benzinga
Nov-23-20 08:00AM	Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-19-20 08:00AM	Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck GlobeNewswire
Nov-17-20 04:01PM	Cue Biopharma Reports Third Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates GlobeNewswire
Nov-11-20 08:00AM	Cue Biopharma to Present at Upcoming Investor Conferences in November 2020 GlobeNewswire
Nov-10-20 08:00AM	Cue Biopharma to Host Business Update Call and Webcast GlobeNewswire +6.74%
Nov-09-20 08:00AM	Cue Biopharma Announces Presentations Highlighting Clinical Progress of CUE-101, Pipeline Progress of CUE-100 Series Immuno-STATs and Immuno-STAT Data for Infectious Disease Applications at the Society for Immunotherapy of Cancers (SITC) 35th Anniversary Annual Meeting GlobeNewswire
Nov-03-20 06:25AM	Did Cue Biopharma's (NASDAQ:CUE) Share Price Deserve to Gain 28%? Simply Wall St.
Oct-19-20 08:00AM	Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 35th Anniversary Annual Meeting GlobeNewswire
Oct-14-20 11:30AM	Hedge Funds Keep Buying Cue Biopharma, Inc. (CUE) Insider Monkey
Sep-17-20 08:00AM	Cue Biopharma Welcomes Tamar Howson to its Board of Directors GlobeNewswire
Sep-15-20 08:00AM	Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds GlobeNewswire
Sep-10-20 08:36AM	Cue Biopharma (CUE) Catches Eye: Stock Jumps 5.2% Zacks
Sep-04-20 10:07AM	Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth Simply Wall St.
Sep-03-20 08:00AM	Cue Biopharma to Present at Upcoming Investor Conferences in September 2020 GlobeNewswire -7.40%
Aug-31-20 04:01PM	Cue Biopharma Reports Second Quarter 2020 Results and CUE-101 Phase 1 Dose Escalation Trial Updates GlobeNewswire
Aug-24-20 08:00AM	Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit GlobeNewswire -6.44%
Aug-17-20 08:00AM	Cue Biopharma to Host Business Update Call and Webcast GlobeNewswire +5.55%
Aug-06-20 12:30PM	Cue Biopharma, Inc. (CUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-28-20 08:00AM	Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent/Metastatic Head and Neck Cancer GlobeNewswire
Jul-08-20 08:00AM	Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily GlobeNewswire
Jul-06-20 02:36PM	Here's What Cue Biopharma, Inc.'s (NASDAQ:CUE) Shareholder Ownership Structure Looks Like Simply Wall St.
Jun-27-20 09:12PM	Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE) Insider Monkey
Jun-15-20 08:00AM	Cue Biopharma Provides Update on Ongoing Phase 1 Trial Evaluating CUE-101 in Recurrent/Metastatic Head and Neck Cancer GlobeNewswire +7.63%
May-28-20 08:00AM	Cue Biopharma to Present Corporate Overview and Pipeline Progress at Jefferies Virtual Healthcare Conference GlobeNewswire
May-20-20 09:01PM	Cue Biopharma, Inc. (CUE) Q1 2020 Earnings Call Transcript Motley Fool +6.01%
May-19-20 10:00PM	Cue Biopharma, Inc. (CUE) Q1 2020 Earnings Call Transcript Motley Fool

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morich Frank	Director	May 27	Buy	3.75	28,000	105,000	28,000	May 31 04:06 PM
Fletcher Aaron G.L.	Director	May 24	Buy	3.34	55,000	183,700	940,000	May 25 09:09 AM
Fletcher Aaron G.L.	Director	May 23	Buy	3.52	150,000	528,000	885,000	May 25 09:09 AM
Fletcher Aaron G.L.	Director	Mar 31	Buy	4.76	735,000	3,498,600	735,000	Apr 04 05:28 PM
Kiener Peter A	Director	Nov 16	Option Exercise	2.86	1,361	3,892	1,361	Nov 17 05:00 PM
Kiener Peter A	Director	Nov 16	Sale	18.02	1,361	24,525	0	Nov 17 05:00 PM
Suri Anish	President and CSO	Nov 15	Option Exercise	8.26	8,000	66,080	102,038	Nov 17 05:00 PM
Kiener Peter A	Director	Nov 15	Option Exercise	2.86	18,815	53,811	18,815	Nov 17 05:00 PM
Kiener Peter A	Director	Nov 15	Sale	17.92	18,815	337,165	0	Nov 17 05:00 PM
Suri Anish	President and CSO	Nov 15	Sale	18.05	8,000	144,400	94,038	Nov 17 05:00 PM
Suri Anish	President and CSO	Nov 11	Option Exercise	6.42	20,000	128,400	114,038	Nov 15 05:00 PM
Suri Anish	President and CSO	Nov 11	Sale	15.07	20,000	301,354	94,038	Nov 15 05:00 PM
Millar Kerri-Ann	CHIEF FINANCIAL OFFICER	Oct 01	Option Exercise	7.50	1,251	9,382	11,723	Oct 05 07:21 PM
Millar Kerri-Ann	CHIEF FINANCIAL OFFICER	Oct 01	Sale	14.21	1,251	17,783	10,472	Oct 05 07:21 PM
PASSERI DANIEL R	CHIEF EXECUTIVE OFFICER	Sep 24	Buy	14.72	3,400	50,051	55,377	Sep 27 04:30 PM
Suri Anish	PRESIDENT AND CSO	Sep 23	Option Exercise	6.42	20,000	128,400	94,838	Sep 27 04:30 PM
Suri Anish	PRESIDENT AND CSO	Sep 23	Sale	15.23	20,000	304,646	74,838	Sep 27 04:30 PM
Millar Kerri-Ann	CHIEF FINANCIAL OFFICER	Aug 23	Option Exercise	0.00	6,667	0	12,433	Oct 05 07:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience